Kornitzer Capital Management Inc. KS Has $13.22 Million Stake in GSK plc (NYSE:GSK)

Kornitzer Capital Management Inc. KS lessened its holdings in GSK plc (NYSE:GSK - Free Report) by 14.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 356,674 shares of the pharmaceutical company's stock after selling 58,853 shares during the period. Kornitzer Capital Management Inc. KS's holdings in GSK were worth $13,218,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Versant Capital Management Inc increased its position in shares of GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company's stock worth $26,000 after purchasing an additional 676 shares during the last quarter. Fairfield Bush & CO. bought a new stake in shares of GSK in the 2nd quarter worth about $28,000. BKM Wealth Management LLC bought a new stake in shares of GSK in the 4th quarter worth about $32,000. Larson Financial Group LLC increased its position in shares of GSK by 271.8% in the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company's stock worth $32,000 after purchasing an additional 647 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in shares of GSK by 61.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company's stock valued at $42,000 after buying an additional 368 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Up 1.2 %

GSK traded up $0.48 on Friday, reaching $39.75. 1,623,882 shares of the company traded hands, compared to its average volume of 2,849,690. The stock's 50 day moving average price is $41.89 and its 200-day moving average price is $38.81. GSK plc has a 52-week low of $33.33 and a 52-week high of $43.84. The company has a market cap of $82.38 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 1.38 and a beta of 0.64. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts' consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The company had revenue of $10 billion for the quarter, compared to analysts' expectations of $9.79 billion. On average, sell-side analysts expect that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were given a dividend of $0.3564 per share. The ex-dividend date was Thursday, February 22nd. This is an increase from GSK's previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a yield of 3.59%. GSK's payout ratio is presently 52.82%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Guggenheim raised shares of GSK from a "neutral" rating to a "buy" rating in a report on Monday, March 4th. Citigroup upgraded shares of GSK from a "neutral" rating to a "buy" rating in a research report on Tuesday, February 13th. Morgan Stanley began coverage on shares of GSK in a research report on Tuesday, January 23rd. They set an "equal weight" rating on the stock. Finally, Jefferies Financial Group upgraded shares of GSK from a "hold" rating to a "buy" rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, GSK presently has a consensus rating of "Moderate Buy".

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.